Kiniksa Pharmaceuticals Ltd (KNSA)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Sanj K. Patel
Employees:
220
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON, BERMUDA HM11
7814399100

Kiniksa Pharmaceuticals, Ltd. focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease. KPL-404 is a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation.

Data derived from most recent annual or quarterly report
Market Cap 528.706 Million Shares Outstanding34.806 Million Avg 30-day Volume 368.951 Thousand
P/E Ratio3.8212 Dividend Yield0.0 EPS2.82
Price to Revenue3.1757 Debt to Equity0.0 EBITDA25.982 Million
Price to Book Value1.924 Operating Margin9.2648 Enterprise Value563.034 Million
Current Ratio6.327 EPS Growth2.433 Quick Ratio5.328
1 Yr BETA 0.6633 52-week High/Low 17.2 / 7.8 Profit Margin83.061
Operating Cash Flow Growth131.2025 Altman Z-Score8.1875 Free Cash Flow to Firm -9.639 Million
Earnings Report2023-08-02
View SEC Filings from KNSA instead.

View recent insider trading info

Kiniksa Pharmaceuticals Ltd YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding KNSA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KNSA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-04-28 by Ragosa Mark
  • 4: filed on 2023-04-11 by MEGNA MICHAEL R
  • 4: filed on 2023-04-11 by MOAT ROSS
  • 4: filed on 2023-04-11 by PAOLINI JOHN F.
  • 4: filed on 2023-04-11 by PATEL SANJ K
  • 4: filed on 2023-04-11 by Ragosa Mark
  • 4: filed on 2023-04-11 by TESSARI EBEN
  • 4: filed on 2023-04-03 by PAOLINI JOHN F.
  • 4: filed on 2023-04-03 by Ragosa Mark
  • 4: filed on 2023-04-03 by TESSARI EBEN

    • Events (8k)

  • 8-K: filed on 2023-05-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-13:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-03:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-30:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    25.3 Thousand total shares from 7 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    RAGOSA MARK CHIEF FINANCIAL OFFICER

    • Officer
    		 12,414 2023-04-26 5

    MEGNA MICHAEL R CHIEF ACCOUNTING OFFICER

    • Officer
    		 12,977 2023-04-10 5

    PATEL SANJ K CHAIRMAN & CEO

    • Officer
    • Director
    		 235,705 2023-04-10 4

    PAOLINI JOHN F. CHIEF MEDICAL OFFICER

    • Officer
    		 41,910 2023-04-10 5

    MOAT ROSS CHIEF COMMERCIAL OFFICER

    • Officer
    		 12,553 2023-04-10 4

    TESSARI EBEN CHIEF OPERATING OFFICER

    • Officer
    		 120,067 2023-04-10 4

    QUART BARRY D

    • Director
    		 0 2022-11-29 2

    BAKER BROS. ADVISORS LP

    667, L.P.

    BAKER JULIAN

    BAKER FELIX

    BAKER BROS. ADVISORS (GP) LLC

    BAKER BROTHERS LIFE SCIENCES LP

    • Director
    		 2,834,417 2022-06-29 1

    POPOVITS KIMBERLY J

    • Director
    		 35,000 2022-06-29 1

    COLE G BRADLEY

    • Director
    		 35,000 2022-06-29 1

    MALLEY THOMAS

    • Director
    		 106,967 2022-06-29 1

    LEVY RICHARD S

    • Director
    		 35,000 2022-06-29 1

    MCCAIN TRACEY L

    • Director
    		 35,000 2022-06-29 1

    PANO ARIAN CHIEF CLINICAL DEV. OFFICER

    • Officer
    		 27,213 2021-09-02 0

    BEETHAM THOMAS W. EVP & CHIEF LEGAL OFFICER

    • Officer
    		 10,142 2021-03-20 0

    RIZVI QASIM CHIEF COMMERCIAL OFFICER

    • Officer
    		 5,176 2020-12-31 0

    HEBERLIG CHRIS EVP & CFO

    • Officer
    		 0 2019-09-17 0

    MAHONEY STEPHEN F. PRESIDENT & COO

    • Officer
    		 0 2019-09-17 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD PARTNERS, L.P.

    • 10% Owner
    • *POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP
    		 No longer subject to file 2018-05-29 0

    BOESS CARSTEN

    • 10% Owner
    		 No longer subject to file 2018-05-29 0

    CORMORANT ASSET MANAGEMENT, LP

    CHEN BIHUA

    CORMORANT GLOBAL HEALTHCARE GP, LLC

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

    • Director
    • 10% Owner
    		 No longer subject to file 2018-05-29 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    • 10% Owner
    • *POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP
    		 0 2018-05-23 0

    BIGGAR STEPHEN R

    • Director
    		 0 2018-05-23 0

    CORMORANT ASSET MANAGEMENT, LP

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

    CORMORANT PRIVATE HEALTHCARE FUND I, LP

    CHEN BIHUA

    • Director
    • 10% Owner
    		 0 2018-05-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    RAGOSA MARK - Officer CHIEF FINANCIAL OFFICER

    		2023-04-28 16:15:11 -0400 2023-04-26 M 990 a 1,981 direct

    RAGOSA MARK - Officer CHIEF FINANCIAL OFFICER

    		2023-04-28 16:15:11 -0400 2023-04-26 M 990 a 12,705 direct 14.663 19.6721 24.6812 5 0.0 1

    RAGOSA MARK - Officer CHIEF FINANCIAL OFFICER

    		2023-04-28 16:15:11 -0400 2023-04-26 F 291 $11.15 d 12,414 direct 14.663 19.6721 24.6812 5 0.0 1

    PATEL SANJ K - Director - Officer CHAIRMAN & CEO

    		2023-04-11 17:05:23 -0400 2023-04-10 M 9,992 a 45,507 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    MEGNA MICHAEL R - Officer CHIEF ACCOUNTING OFFICER

    		2023-04-11 17:07:19 -0400 2023-04-10 M 3,933 a 11,797 direct

    MEGNA MICHAEL R - Officer CHIEF ACCOUNTING OFFICER

    		2023-04-11 17:07:19 -0400 2023-04-10 M 3,933 a 14,132 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    MEGNA MICHAEL R - Officer CHIEF ACCOUNTING OFFICER

    		2023-04-11 17:07:19 -0400 2023-04-10 F 1,155 $10.71 d 12,977 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    RAGOSA MARK - Officer CHIEF FINANCIAL OFFICER

    		2023-04-11 17:04:50 -0400 2023-04-10 M 2,695 a 8,082 direct

    RAGOSA MARK - Officer CHIEF FINANCIAL OFFICER

    		2023-04-11 17:04:50 -0400 2023-04-10 M 2,695 a 12,506 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    RAGOSA MARK - Officer CHIEF FINANCIAL OFFICER

    		2023-04-11 17:04:50 -0400 2023-04-10 F 791 $10.71 d 11,715 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    PATEL SANJ K - Director - Officer CHAIRMAN & CEO

    		2023-04-11 17:05:23 -0400 2023-04-10 M 9,992 a 29,975 direct

    TESSARI EBEN - Officer CHIEF OPERATING OFFICER

    		2023-04-11 17:03:54 -0400 2023-04-10 F 801 $10.71 d 120,067 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    PATEL SANJ K - Director - Officer CHAIRMAN & CEO

    		2023-04-11 17:05:23 -0400 2023-04-10 F 2,933 $10.71 d 42,574 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    PAOLINI JOHN F. - Officer CHIEF MEDICAL OFFICER

    		2023-04-11 17:06:03 -0400 2023-04-10 M 2,498 a 7,492 direct

    PAOLINI JOHN F. - Officer CHIEF MEDICAL OFFICER

    		2023-04-11 17:06:03 -0400 2023-04-10 M 2,498 a 42,644 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    PAOLINI JOHN F. - Officer CHIEF MEDICAL OFFICER

    		2023-04-11 17:06:03 -0400 2023-04-10 F 734 $10.71 d 41,910 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    MOAT ROSS - Officer CHIEF COMMERCIAL OFFICER

    		2023-04-11 17:06:38 -0400 2023-04-10 M 2,477 a 7,431 direct

    MOAT ROSS - Officer CHIEF COMMERCIAL OFFICER

    		2023-04-11 17:06:38 -0400 2023-04-10 M 2,477 a 13,906 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    MOAT ROSS - Officer CHIEF COMMERCIAL OFFICER

    		2023-04-11 17:06:38 -0400 2023-04-10 F 1,353 $10.71 d 12,553 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    TESSARI EBEN - Officer CHIEF OPERATING OFFICER

    		2023-04-11 17:03:54 -0400 2023-04-10 M 2,727 a 8,178 direct

    TESSARI EBEN - Officer CHIEF OPERATING OFFICER

    		2023-04-11 17:03:54 -0400 2023-04-10 M 2,727 a 120,868 direct 9.0994 10.8818 32.4578 34.6154 24 0.0 1

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-07 13:45:03 UTC 4.5722 0.4978 550000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-07 13:15:04 UTC 4.5722 0.4978 650000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-07 12:45:04 UTC 4.5722 0.4978 650000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 22:15:03 UTC 4.5722 0.4978 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 21:45:05 UTC 4.5722 0.4978 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 21:15:04 UTC 4.5722 0.4978 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 20:45:04 UTC 4.5722 0.4978 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 20:15:04 UTC 4.5722 0.4978 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 19:45:04 UTC 4.5722 0.4978 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 19:15:03 UTC 4.5722 0.4978 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 18:45:04 UTC 4.5722 0.4978 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 18:15:04 UTC 4.5722 0.4978 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 17:45:04 UTC 4.5722 0.4978 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 17:15:04 UTC 4.5722 0.4978 850000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 16:45:04 UTC 4.5673 0.4927 850000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 16:15:03 UTC 4.5673 0.4927 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 15:45:04 UTC 4.5673 0.4927 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 15:15:04 UTC 4.5673 0.4927 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 14:45:04 UTC 4.5673 0.4927 700000
    KINIKSA PHARMACEUTICALS-A KNSA 2023-06-06 14:15:03 UTC 4.5673 0.4927 850000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund KNSA -1000.0 shares, $-10760.0 2023-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments